The appeal of a lower price is understandable, especially when retatrutide costs significantly more than simpler peptides
Liraglutide , taken daily: FDA-approved under the brand name Saxenda for chronic weight management alongside diet and exercise in adults with a body mass index (BMI) of 30 or higher or a BMI of 27 or higher with a weight-related medical condition or in children ages 12 years and older with obesity who weigh at least 132 pounds
These medications, including semaglutide and liraglutide, reduce appetite and slow gastric emptying, leading to decreased caloric intake and subsequent weight reduction in patients with obesity or overweight conditions with metabolic complications
Addressing type 2 diabetes requires frequent monitoring and consultations that are difficult, if not impossible, to manage through telehealth alone
A New Generation of Metabolic Research Retatrutide is a next-generation research peptide developed to target three key metabolic receptor pathways simultaneously: GLP-1, GIP, and glucagon (GCGR)